PRAK Suppresses Oncogenic ras-Induced Hematopoietic Cancer Development by Antagonizing the JNK Pathway

The p38 mitogen-activated protein kinase (MAPK) pathway regulates multiple physiologic and pathologic processes, including cancer development. PRAK, a p38 substrate protein kinase, has previously been implicated in the suppression of skin carcinogenesis. In the current study, we show that PRAK deletion accelerates hematopoietic cancer development in a mouse model harboring an oncogenic ras allele, Eμ-N-RasG12D, specifically expressed in hematopoietic cells. Further investigation reveals that enhanced hematopoietic tumorigenesis by PRAK deficiency is associated with hyperactivation of the c-jun-NH2-kinase (JNK) pathway both in vivo and in primary hematopoietic cells isolated from spleens. In primary splenocytes, PRAK deficiency further enhanced oncogenic ras-induced cell proliferation and promoted ras-mediated colony formation on semisolid medium in a JNK-dependent manner. In addition, deletion of PRAK leads to abrogation of ras-induced accumulation of senescence markers. These findings indicate that PRAK suppresses hematopoietic cancer formation in this mouse model by antagonizing oncogenic ras-induced activation of the JNK pathway. Our results suggest that PRAK may function as a tumor suppressor in multiple types of cancers. Mol Cancer Res; 10(6); 810–20. ©2012 AACR.

[1]  J. Pollack,et al.  c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells , 2007, Oncogene.

[2]  J. D. Di Santo,et al.  c-Jun NH2-terminal kinase/c-Jun signaling promotes survival and metastasis of B lymphocytes transformed by Theileria. , 2006, Cancer research.

[3]  G. Hannon,et al.  p53-independent role of MDM2 in TGF-beta1 resistance. , 1998, Science.

[4]  M. Barbacid,et al.  p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. , 2007, Nature genetics.

[5]  M. Barbacid,et al.  Tumour biology: Senescence in premalignant tumours , 2005, Nature.

[6]  Christian Haslinger,et al.  p38α suppresses normal and cancer cell proliferation by antagonizing the JNK–c-Jun pathway , 2007, Nature Genetics.

[7]  M. Gaestel,et al.  In the Cellular Garden of Forking Paths: How p38 MAPKs Signal for Downstream Assistance , 2002, Biological chemistry.

[8]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[9]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[10]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[11]  Michel Morange,et al.  A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins , 1994, Cell.

[12]  R. Flavell,et al.  Defective T cell differentiation in the absence of Jnk1. , 1998, Science.

[13]  D. Vaux,et al.  Transgenic mouse models for hematopoietic tumorigenesis. , 1988, Current topics in microbiology and immunology.

[14]  J. Yates,et al.  PRAK Is Essential for ras-Induced Senescence and Tumor Suppression , 2007, Cell.

[15]  E. Ranheim,et al.  Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner. , 2011, Blood.

[16]  Yong Jiang,et al.  PRAK, a novel protein kinase regulated by the p38 MAP kinase , 1998, The EMBO journal.

[17]  Jason A. Koutcher,et al.  Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis , 2005, Nature.

[18]  M. Serrano,et al.  The power and the promise of oncogene-induced senescence markers , 2006, Nature Reviews Cancer.

[19]  S. Lowe,et al.  Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[20]  G. Hannon,et al.  p53-Independent Role of MDM2 in TGF-β1 Resistance , 1998 .

[21]  J. Shay,et al.  Senescence and immortalization: role of telomeres and telomerase. , 2005, Carcinogenesis.

[22]  T. Jacks,et al.  Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. , 2011, Blood.

[23]  P. Ling,et al.  Leukocyte-specific adaptor protein Grap2 interacts with hematopoietic progenitor kinase 1 (HPK1) to activate JNK signaling pathway in T lymphocytes , 2001, Oncogene.

[24]  E. Wagner,et al.  Control of cell cycle progression by c-Jun is p53 dependent. , 1999, Genes & development.

[25]  H. Stein,et al.  Oncogene-induced senescence as an initial barrier in lymphoma development , 2005, Nature.

[26]  Albert J. Fornace,et al.  Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity , 2002, Nature Genetics.

[27]  G. Hannon,et al.  MaRX: An Approach to Genetics in Mammalian Cells , 1999, Science.

[28]  L Bibbs,et al.  A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. , 1994, Science.

[29]  M. Fleming,et al.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. , 2010, Blood.

[30]  Peiqing Sun,et al.  The pathways to tumor suppression via route p38. , 2007, Trends in biochemical sciences.

[31]  Jiahuai Han,et al.  The p38 Pathway Provides Negative Feedback for Ras Proliferative Signaling* , 2000, The Journal of Biological Chemistry.

[32]  E. Wagner,et al.  Distinct roles for JNK1 and JNK2 in regulating JNK activity and c-Jun-dependent cell proliferation. , 2004, Molecular cell.

[33]  L. Donehower,et al.  Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK–mediated activation of the p16Ink4a-p19Arf pathway , 2004, Nature Genetics.